Everything below concerns Laboratory compound. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-12. Numbers and descriptions here follow the published literature rather than marketing material.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common for reference-grade material. |
| Solubility | Low in water | Dissolves in DMSO and some organic solvents. |
| Typical storage | -20 °C, desiccated | Protect from light and moisture. |
| Analytical method | LC-MS/MS | Used for trace detection in biological matrices. |
| Purity assessment | HPLC with UV detection | Often combined with NMR and mass spectrometry. |
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
== Acquisitions and expansion == In 2012, the company acquired Stanford Refrigerated Warehouses and Castle & Cooke Cold Storage; Bill Hendricksen of Castle & Cooke then joined Lineage as CEO. Hendricksen was succeeded by W. Gregory Lehmkuhl, in July 2015. Lineage subsequently moved its headquarters from Irvine, California to Novi, Michigan. In April 2013, the company received a $220 million loan, and acquired Seattle Cold Storage and a University Park, Illinois facility. By 2014, most Lineage customers were food producers requiring cold chain warehousing, transportation, and logistics; to meet demand, the company concentrated on automation and acquisition. In March 2014, the company agreed to purchase Millard Refrigerated Services for about $1 billion, its largest acquisition to date, making Lineage "the second-largest temperature-controlled warehousing and logistics company in the world." In the same year, Lineage acquired Loop Cold Storage, Oneida Cold Storage & Warehouse, Murphy Overseas, and two facilities in Watsonville, California from Dreisbach Enterprises and in September 2014, opened a new temperature-controlled warehouse in Santa Maria, California. In January 2015, Lineage acquired the Pacific Northwest cold storage facilities of Columbia Colstor, headquartered in Moses Lake, Washington.
Although the concern over the effects began to grow, the violent depictions remained the same. In a 1989 longitudinal study conducted by the Cultural Indicators Project, they analyzed the portrayal of mentally ill characters on 1,215 television programs between 1969 and 1985. They found that 3 out of 4 characters were involved in violent situations, either becoming victims of violence or perpetrating it. In addition to the mentally ill characters having violent tendencies, they also were distancing themselves from loved ones, and often did not work. Finally, nearly 50 years after one of the inaugural studies that analyzed the overuse of mentally ill, violent characters in media, the misconception persists, even into the 21st century. Diefenbach and West conducted a cultivation study that examined 84 hours of prime-time television among major networks in April 2003. They found that mentally ill characters on television were much more likely to commit violent crimes than real-world statistics. Only 4% of people with mental illnesses in the real world are characterized as violent, while 37% of mentally ill characters on television are portrayed as violent.
Since 1997, the US federal government has prohibited the harvesting of white sharks in US waters, requiring that any incidentally caught shark be released immediately. Management of the species is split by region: the 2006 Consolidated Atlantic Highly Migratory Species Fishery Management Plan covers the Atlantic, while the Pacific Fishery Management Council oversees the Pacific. The white shark also receives protection in National Marine Sanctuaries managed by the National Oceanic and Atmospheric Administration. Some states provide additional safeguards. California has protected the species within its waters (up to 3 miles (4.8 km) offshore) since 1994 and in 2013, added white sharks to the California Endangered Species Act, which introduced strict permit requirements for both scientific research and incidental bycatch. In 2019, the state further banned the use of bait, chum, or decoys to lure white sharks in state waters and prohibited their use within one nautical mile of any shoreline or pier when a shark is present. A 2014 study estimated the white shark population along the California coastline to be approximately 2,400 individuals. Massachusetts also provides state-level protection, having prohibited the capture of white sharks in 2005 and banning the use of chum or bait to lure them in 2015. In 2025, authorities restricted shore-based fishing around Cape Cod in response to viral videos of anglers catching white sharks.
Sources: en.wikipedia.org
==== Antarctic plate ==== Marion hotspot (25) 46°54′S 37°36′E, w= 0.5 az= 080° ±12° Crozet hotspot (52) 46°06′S 50°12′E, w= 0.8 az= 109° ±10° rate= 25 ±13 mm/yr Possibly related to the Karoo-Ferrar geologic province (183 Ma) Kerguelen hotspot (20) 49°36′S 69°00′E, w= 0.2 az= 050° ±30° rate= 3 ±1 mm/yr Related to the Kerguelen Plateau (130 Ma) Heard hotspot (53), possibly part of Kerguelen hotspot 53°06′S 73°30′E, w= 0.2 az= 030° ±20° Île Saint-Paul and Île Amsterdam could be part of the Kerguelen hotspot trail (St. Paul is possibly not another hotspot) Balleny hotspot (2) 67°36′S 164°48′E, w= 0.2 az= 325° ±7° Erebus hotspot (54) 77°30′S 167°12′E
During the period when Germany was divided, the Lower Saxon border crossing at Helmstedt found itself on the main transport artery to West Berlin and, from 1945 to 1990 was the busiest European border crossing point. Of economic significance for the state was the Volkswagen concern, that restarted the production of civilian vehicles in 1945, initially under British management, and in 1949 transferred into the ownership of the newly founded country of West Germany and state of Lower Saxony. Overall, Lower Saxony, with its large tracts of rural countryside and few urban centres, was one of the industrially weaker regions of the federal republic for a long time. In 1960, 20% of the working population worked on the land. In the rest of the federal territory the figure was just 14%. Even in economically prosperous times the jobless totals in Lower Saxony are constantly higher than the federal average. In 1961 Georg Diederichs took office as the minister president of Lower Saxony as the successor to Hinrich Wilhelm Kopf. He was replaced in 1970 by Alfred Kubel. The arguments about the Gorleben Nuclear Waste Repository, that began during the time in office of minister president Ernst Albrecht (1976–1990), have played an important role in state and federal politics since the end of the 1970s. In 1990 Gerhard Schröder entered the office of minister-president. On 1 June 1993, the new Lower Saxon constitution entered force, replacing the "Provisional Lower Saxon Constitution" of 1951.
=== Insomnia === Orexin receptor antagonists dose-dependently improve sleep parameters including latency to persistent sleep (LPS), wake after sleep onset (WASO), sleep efficiency (SE), total sleep time (TST), and sleep quality (SQ). Orexin receptor antagonists are not currently used as first-line treatments for insomnia due to cost and concerns about possible misuse liability.
Caffeine has been found to increase striatal dopamine in animal models, as well as inhibit the inhibitory effect of adenosine receptors on dopamine receptors, however the implications for humans are unknown. Unlike most stimulants, caffeine has no addictive potential. Caffeine does not appear to be a reinforcing stimulus, and some degree of aversion may actually occur, per a study on drug abuse liability published in a NIDA research monograph that described a group preferring placebo over caffeine. In large telephone surveys only 11% reported dependence symptoms. However, when people were tested in labs, only half of those who claim dependence actually experienced it, casting doubt on caffeine's ability to produce dependence and putting societal pressures in the spotlight. Coffee consumption is associated with a lower overall risk of cancer. This is primarily due to a decrease in the risks of hepatocellular and endometrial cancer, but it may also have a modest effect on colorectal cancer. There does not appear to be a significant protective effect against other types of cancers, and heavy coffee consumption may increase the risk of bladder cancer. A protective effect of caffeine against Alzheimer's disease is possible, but the evidence is inconclusive. Moderate coffee consumption may decrease the risk of cardiovascular disease, and it may somewhat reduce the risk of type 2 diabetes. Drinking 1–3 cups of coffee per day does not affect the risk of hypertension compared to drinking little or no coffee.
Sources: en.wikipedia.org
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.
Reference material is usually kept cold, dry, and protected from light. Frozen aliquots reduce repeated freeze-thaw cycles.
No approved pharmaceutical product exists, so manufacturing and quality controls are not standardized. Products may contain different compounds or impurities.
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.